International Faculty

#
#

Dr. Guillermo E. Umpierrez,USA
Dr. Umpierrez is professor of medicine in the division of endocrinology, metabolism at Emory University School of Medicine, and chief of diabetes and endocrinology at Grady Memorial Hospital
Area of Specialty: Endocrinology, Diabetes and Metabolism
Dr. Umpierrez first joined the Emory University School of Medicine faculty in 1992 – 1997. He returned in 2003 to focus on diabetes and metabolic disorders. Dr. Umpierrez's research interests include mechanisms for ß-cell dysfunction in minority populations with ketosis-prone type 2 diabetes, the effects of free fatty acids on insulin secretion and hypertension in obese patients, and the inpatient management of insulin in critical and non-critical patients. His research programs at Grady Hospital and Emory University are funded by the National Institutes of Health (NIH), American Diabetes Association (ADA), and American Heart Association (AHA)

In 2009, Dr. Umpierrez received “Outstanding Service Award for the Promotion of Endocrine Health of an Underserved Population” by the American Association of Clinical Endocrinologists (AACE). The Outstanding Service Award the Promotion of Endocrine Health of an Underserved Population is given to an individual for exceptional contributions to the care, health, and service to an underserved population via leadership, long-term commitment, vision, innovation, and impact/outcomes.
Dr. Umpierrez heads the Emory Latino Diabetes Education Program (ELDEP), the first nationally accredited all Spanish Diabetes education program dedicated to providing diabetes education and lifestyle intervention to Latinos in Georgia

Under his leadership, the ELDEP has received funding in the amount close to $500,000 from the Healthcare Georgia Foundation and the pharmaceutical industry to develop a culturally sensitive, community-based diabetes education program targeting Latinos in metro Atlanta and throughout the state of Georgia. Umpierrez spearheaded the development of a video produced by the ELDEP "Viva mas y major…con su diabetes bajo control!" live longer and better with your diabetes under control!

Personal Statement:
I am committed to the mission of Grady and feel both honored and humbled by the opportunity to help the indigent and inner city population. I am motivated every day to continue to serve and to develop mechanisms to assure quality diabetes care in this vulnerable patient population at high risk for diabetes complications.

#

Prof Vivian A. Fonseca, MD, FRCP, USA
Tullis–Tulane Alumni Chair in Diabetes
Professor of Medicine & Chief, Section of Endocrinology
Dr. Fonseca serves on the clinical practice committee of the American Diabetes Association (current chairman) and the joint ADA/ACC “Make the Link” Program. He is the President of Medicine & Science for the American Diabetes Association
He is editor-in-chief of Diabetes Care since 2007, having formerly been associate editor. He was until 2006 editor-in-chief of the Journal of the Metabolic Syndrome and related disorders. He served on the editorial board of the Journal of Clinical Endocrinology and Metabolism (2003-2006). He is an ad hoc reviewer for several other journals including New England Journal of Medicine, JAMA, Diabetes, Diabetic Medicine, Kidney International, the American Journal of Clinical Nutrition, the British Medical Journal, and Metabolism. Dr. Fonseca is a fellow of the American Association of Clinical Endocrinologists, the Royal College of Physicians (London), and the American College of Physicians. He is a member of the Endocrine Society, the American Diabetes Association, and the International Diabetes Federation. He serves on several national and international committees, and has published over 200 papers, review articles and book chapters.

Research Interests
Dr. Fonseca's current research interests include the prevention and treatment of diabetic complications and risk factor reduction in cardiovascular disease. He has a research program evaluating homocysteine and inflammation as risk factors for heart disease in diabetes. He is currently the principal investigator of the DRMS (diabetes remote management system) study, a study aimed at evaluating the effectiveness and possibilities of using a remote technology system to enhance and manage daily care for patients with Type 2 Diabetes Mellitus. Dr. Fonseca is also the principal investigator of the Zemplar study, a study investigating the effects of Zemplar (paricalcitol) on endothelial function and inflammation in patients with Type 2 Diabetes Mellitus and stage 3 or 4 chronic kidney disease.

He is also the principal investigator of the ACCORDION study, an NIH sponsored, multicenter follow –up study to the ACCORD study which examined cardiovascular risk and diabetes. Dr. Fonseca is also the principal investigator for the BEACON study, a multicenter study evaluating the effects of bardoxolone methyl in patients with chronic kidney disease and Type 2 diabetes. Dr. Fonseca has lectured in the United States and abroad, and his publications include more than 180 articles. He is the editor of the text book "Clinical Diabetes: Translating Research into Practice" (El Sevier 2006) and several monographs and book chapters.

#

Dr Paresh Dandona MD, PhD, USA
Department of Medicine
SUNY Distinguished Professor and Chief, Endocrinology
Specialty/Research Focus
Endocrinology, Diabetes and Metabolism

Professional Summary:
Vascular cell reactivity encompassing platelet function, endothelial function, monocyte/macrophage function and the interactions between them (adhesion molecules viz lCAM, VCAM, P-selectin, L-selectin, E-selectin, etc.). Reactive Oxygen Species (ROS) in diabetes, atherosclerosis, hypertension, aging, infection, etc. and a consequential damage to lipids, proteins and DNA. Regulation of aromatase, the effect of estrogen on estrogen receptor, androgen receptor and glucocortico receptor (elucidationi of pre- and post-receptor mechanisms in menopause, etc.). Venous reactivity with measurements of venous diameter and flow velocity and the effect of various drugs in NIDDM, IDDM, and IGT. Genetic regulation of aromatase and estrogen receptor. The role of nitric oxide in vascular reactivity, vis-a-vis various complications of diabetes and other factors involved with vascular reactivity. Effects of endotoxin on adhesion molecules, PAF, platelets, ROS and procalcitonin.

  • SUNY Distinguished Professor, Medicine, University at Buffalo (2011-present)
  • Professor, University at Buffalo (1996-present)
  • Founder & Medical Director, Diabetes-Endocrinology Center of Western New York (1995-present)
  • Chief, Kaleida Health (1991-present)
  • Professor, Medicine, University at Buffalo (1991-present)


Awards and Honors:

  • Pharmacia Award (2002)
  • Valor Award (2001)
  • Distinguished Service Award (2001)
  • Madhav Award (1997)
  • Alert Award (1996)
  • Distinguished Service Award (1993)
  • Rhodes Scholarship (1966)
#

Dr Arya M. Sharma, Canada
Scientific Director

Arya M. Sharma is the Scientific Director of CON, a Professor of Medicine, and the Chair for Obesity Research & Management at the University of Alberta.
Arya M. Sharma (Scientific Director) - Professor of Medicine, Chair for Obesity Research & Management, University of Alberta; Medical Director, Weight Wise, Edmonton Alberta Health Services Region.

Dr. Arya M. Sharma, MD/PhD, FRCPC is Professor of Medicine & Chair for Cardiovascular Obesity Research and Management at the University of Alberta, Edmonton, Canada. He is also the Medical Director of the Edmonton Capital Health Region’s interdisciplinary Weight Wise Program.

Dr. Sharma is also the Scientific Director of the Canadian Obesity Network, originally funded through the federal Networks of Centres of Excellence program.

His past appointments include positions as Professor of Medicine and Canada Research Chair (Tier 1) at McMaster University (2002-2007), Professor of Medicine at the Franz-Volhard Klinik - Charité, Humboldt University Berlin (2000-2002) and the Free University of Berlin (1994-2000). His research focuses on the evidence-based prevention and management of obesity and its complications.

He is a member of several scientific associations, including the Canadian and International Societies of Hypertension. He is a fellow of the Council for High Blood Pressure Research of the American Heart Association and on the editorial board of several academic journals.

#

Dr. Gerry Rayman MD FRCP, UK
Consultant Physician and Diabetologist, Ipswich Hospital NHS Trust
Dr. Gerry Rayman is Head of Service at the Diabetes and Endocrine Centre, Ipswich Hospital NHS Trust. He has been NHS Diabetes’s national clinical lead for the diabetic foot and national lead on inpatient diabetes care. He is the specialist medical advisor to Diabetes UK and clinical lead for their Diabetes Foot Campaign. He is the current President of the Endocrine and Diabetes section of the Royal Society of Medicine.

Dr. Rayman developed the National Diabetes Inpatient Audit and has contributed to several national guidelines on inpatient diabetes care including the JBDS guidelines on DKA, perioperative management and safe discharge. Dr Rayman was involved in development of the National Diabetes Foot Audit launched this year. He has also contributed to several national guideline documents on foot care including both the ‘Putting Feet First’ guidance documents and NICE foot guidelines (CG10 and CG119).

Dr. Rayman’s research interests are diabetic foot complications, new technologies, patient education and service delivery. He has been involved in designing and advising on devices related to diabetes care including insulin pens, glucose meters, glucose sensors, insulin pump cannulae, and devices for assessing skin blood flow and neuropathy.

Dr. Rayman has been prominent in training future diabetologists. He established the Foundation Course in Clinical Diabetes for SpRs, the ABCD SpR meet the expert sessions, and helped set up the Young Diabetologists SpR Forum. He has been involved in organising the national Diabetes UK and RSM conferences and the Malvern international foot conference. He lectures nationally and internationally on the diabetic foot.

#

Allison B. Goldfine, MD
Director, Translational Medicine-Cardiovascular & Metabolism
Novartis Institutes for BioMedical Research

Dr. Goldfine is newly appointed Director of Translational Medicine in Cardiometabolic Disease at the Novartis Institute of Biomedical Research.
Dr. Goldfine is an Associate Professor of Medicine at Harvard Medical School, and the previous Head of the Section of Clinical Research at the Joslin Diabetes Center. Her research has focused on physiologic identification and targeting of pathways relevant to development of type 2 diabetes, and/or cardiovascular complications of the disease. She has extensively evaluated novel interventions targeting the obesity mediated low grade chronic inflammatory state associated with cardiometabolic disease.
In addition, she has studied bariatric surgical approaches to diabetes and weight management to discover mechanisms underlying metabolic improvements following these procedures.
She completed terms on the External Advisory Committee to the Division Metabolic and Endocrine Drug Advisory Committee of the FDA, and on the Practice Guideline Committee for the American Diabetes Association.
She also serves on the American Diabetes Association Research Grant Review Committee for clinical studies.